Siste forsøk

EudraCT Number: 2022-000365-41

Sponsor Protocol Number: CNTO1959UCO3004

Start Date: 2023-04-26

Sponsor Name: Janssen-Cilag International NV

Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Mode...

Medical condition: Moderately to Severely Active Ulcerative Colitis

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004856	10045365	Ulcerative colitis	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing) CZ (Ongoing) HU (Ongoing) BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-001793-36

Sponsor Protocol Number: GTX-102-001

Start Date: 2023-04-26

Sponsor Name: Ultragenyx Pharmaceutical Inc.

Full Title: A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)

Medical condition: Angelman Syndrome

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Ongoing) FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005099-21

Sponsor Protocol Number: MER-XMT-1536-3

Start Date: 2023-04-25

Sponsor Name: Mersana Therapeutics, Inc.

Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensiti...

Medical condition: Recurrent, Platinum-Sensitive Ovarian Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: FR (Ongoing) NO (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) IT (Ongoing) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) NL (Completed)

Trial results: (No results available)

EudraCT Number: 2022-003810-35

Sponsor Protocol Number: BMX-04-001

Start Date: 2023-04-25

Sponsor Name: BiomX Ltd.

Full Title: A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomon...

Medical condition: Cystic fibrosis Chronic Pseudomonas Aeruginosa Infection

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10011763	Cystic fibrosis lung	PT
	22.1	100000004862	10082869	Chronic Pseudomonas aeruginosa infection	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) CZ (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003408-33

Sponsor Protocol Number: ESR-21-21536

Start Date: 2023-04-25

Sponsor Name: TheraOp gGmbH

Full Title: PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC

Medical condition: Locally advanced, unresectable non-small-cell lung cancer (NSCLC) (Stage III) with a PD-L1-expression of ≥ 1%

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001314-19

Sponsor Protocol Number: VO659-CT01

Start Date: 2023-04-25

Sponsor Name: VICO Therapeutics B.V.

Full Title: A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with sp...

Medical condition: spinocerebellar ataxia types 1, 3 and Huntington’s disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.0	10010331 - Congenital, familial and genetic disorders	10057660	Spinocerebellar ataxia	LLT
	20.0	10010331 - Congenital, familial and genetic disorders	10070668	Huntington's disease	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Ongoing) NL (Ongoing) IT (Ongoing) DK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002214-17

Sponsor Protocol Number: NL78220.029.21

Start Date: 2023-04-24

Sponsor Name: Amsterdam University Medical Centers

Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial

Medical condition: Recurrent colorectal liver metastases

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10052358	Colorectal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024700	Liver metastases	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-001413-37

Sponsor Protocol Number: BELI(E)VE-Trial

Start Date: 2023-04-24

Sponsor Name: University Medical Center Hamburg-Eppendorf

Full Title: Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) The BELI(E)VE-Trial

Medical condition: relapsed and refractory t(11;14) Multiple Myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10028228	Multiple myeloma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-003063-10

Sponsor Protocol Number: ARGX-113-2010

Start Date: 2023-04-21

Sponsor Name: argenx BV

Full Title: An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Medical condition: Bullous Pemphigoid

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10040785 - Skin and subcutaneous tissue disorders	10006567	Bullous pemphigoid	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SK (Ongoing) GR (Ongoing) HU (Ongoing) DE (Ongoing) ES (Ongoing) BG (Ongoing) IT (Ongoing) NL (Ongoing) HR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-004155-13

Sponsor Protocol Number: BMS_IM101-931

Start Date: 2023-04-20

Sponsor Name: Universitätsklinikum Freiburg

Full Title: Study to investigate the restoring of an immunological balance during therapy with abatacept Abatacept restores immune system equilibrium (ARISE)

Medical condition: CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positiv...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10021428 - Immune system disorders	10021449	Immunodeficiency common variable	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

Siste forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner